Uncategorized
Eylea yields greatest quality-of-life gain in CRVO treatment
PHILADELPHIA — Aflibercept yielded the greatest increase in patient quality of life in the treatment of central retinal vein occlusion, while bevacizumab was most cost-effective, a speaker told colleagues here.At the Wills Eye Alumni Conference, Bryan K. Hong, MD, described quality-adjusted life-year (QALY) and cost-utility data for Eylea (aflibercept, Regeneron), Avastin (bevacizumab, Genentech) and Lucentis (ranibizumab, Genentech).